In the present study, we expected that individuals with obesity would be more permissive to detecting the potential effects of β-OHB to inhibit NLRP3 activation due to the propensity for elevated baseline inflammation (as evidenced by mean fasting plasma hs-CRP concentration of ~0.4 mg/dL in our sample). Here, NLRP3 is linked to obesity disorder.